SBP target of lower than 120 mmHg reduces CV events in T2DM

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024

Recommended

Details

Presenters

Overview
AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024

SBP target of lower than 120 mmHg reduces risk of CV events in T2DM